Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19

NCT ID: NCT04567173

Last Updated: 2022-05-24

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-21
• Study Completion Date: 2021-06-30

Brief Summary

This protocol provides access to investigational convalescent plasma for hospitalized patients with COVID-19. Following provision of informed consent, patients will be administered around 500 mL of convalescent plasma obtained from an individual who has recovered from a documented SARS-CoV-2 infection. The study aims to evaluate the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as adjunctive therapy in preventing disease progression (prevention of ICU admission) among hospitalized patients with COVID-19. Safety outcomes include serious adverse events judged to be related to convalescent plasma. Other information which will be collected includes patient demographics and clinical data which includes quick SOFA scores, ventilator-free days, ICU-free days, dialysis-free days and 28-day mortality.

Detailed Description

This is a phase 3, randomized, non-placebo controlled, open-label, single-center clinical trial which will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma given from the 3rd to 14th day of illness after the onset of symptoms in preventing ICU admission among hospitalized COVID-19 patients compared to standard of care. Consecutive patients with COVID-19 admitted to the UP Philippine General Hospital will be offered participation into the study. Patients in the intervention group will receive one dose of type-specific anti-SARS-CoV-2 convalescent plasma (500 mL collected by whole blood donation or standard pheresis at the UP-PGH blood bank from a volunteer who recovered from COVID-19). The primary safety endpoints include serious adverse events judged to be related to convalescent plasma. The study also aims to compare anti-SARS-CoV-2 antibody titers and rates, levels, and duration of SARS-CoV-2 RNA in nasopharyngeal swabs using RT-PCR between the intervention and control groups.

Conditions

Covid19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Anti-SARS-CoV-2 convalescent plasma

About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL

Group Type: EXPERIMENTAL

Anti-SARS-CoV-2 convalescent plasma

Intervention Type: DRUG

convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19

Standard of care

Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Anti-SARS-CoV-2 convalescent plasma

convalescent plasma derived from whole blood donors or standard pheresis from a volunteer who recovered from COVID-19

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patient must be 19 years of age or older
• Hospitalized with COVID-19 and confirmed via SARS-CoV-2 RT-PCR testing
• Patient is willing and able to provide written consent and comply with all protocol requirements
• Patient agrees to storage of specimens for future testing

Exclusion Criteria

• Female subjects with positive pregnancy test, are breastfeeding or planning to become pregnant/breastfeed during the study period
• Symptomatic illness exceeding 14 days from onset of illness at time of enrollment
• ICU admission on initial presentation at the hospital (includes patients with clinical indications for ICU admission as follows:

1. Respiratory distress with requirement of O2 >6 lpm to maintain O2 sat >92%

2. Rapid escalation of O2 requirement/significant work of breathing

3. Hemodynamic instability: SBP <90, MAP <65

• Receipt of any blood products including pooled immunoglobulin or intravenous immunoglobulin (IVIg) in the past 30 days prior to enrolment
• Known IgA deficiency
• Presence of any contraindication to transfusion (or history of prior severe reactions to transfusion of blood products)

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of the Philippines

OTHER

Sponsor Role: lead

Responsible Party

Deonne Thaddeus Gauiran

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Deonne Thaddeus V Gauiran, MD

Role: PRINCIPAL_INVESTIGATOR

UP Philippine General Hospital

Locations

UP Philippine General Hospital

Manila, , Philippines

Countries

Philippines

Other Identifiers

PHRR200824-002868

Identifier Type: -

Identifier Source: org_study_id